Hypertension: do we need to consider the biological clock in drug dosing?
نویسندگان
چکیده
منابع مشابه
Biosimilar therapeutics—what do we need to consider?
Patents for the first generation of approved biopharmaceuticals have either expired or are about to expire. Thus the market is opening for generic versions, referred to as 'biosimilars' (European Union) or 'follow-on protein products' (United States). Healthcare professionals need to understand the critical issues surrounding the use of biosimilars to make informed treatment decisions.The compl...
متن کاملRamadan fasting: Do we need more evidence?
Over a billion of Muslims fast worldwide during Ramadan each year. Through this religious custom, fasting contributes to their health as well as their spiritual growth. However, available evidence regarding the health-benefits of Ramadan fasting is scarce and highly contentious. Although Islam exempts patients from fasting, many fast conceivably, and their clinical condition is prone to deterio...
متن کاملStaff Burnout… Do we need any intervention?
Dear Editor, As you know physical and mental wellness of physicians and nurses, as the main role in the treatment of patients, in conditions such as burnout, compassion fatigue, depression, and poor work-life balance, is one of the top priorities in the U.S.A. National Academy of Medicine (1-4). Although healthcare team members are generally known as a caregiver to others; their h...
متن کاملBiosimilars: what do patients need to consider?
A view from the EULAR Standing Committee of People with Arthritis/Rheumatism in Europe (SCPARE) on some of the issues that patients might wish to consider about biosimilars in shared decision-making discussions with their rheumatologist. The paper also points to the need for more information on biosimilars being made available in lay language.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Expert Review of Cardiovascular Therapy
سال: 2007
ISSN: 1477-9072,1744-8344
DOI: 10.1586/14779072.5.3.375